BIM-46174 是一种异源三聚体 G 蛋白复合物 (G protein) 抑制剂,通过将 Gα 蛋白捕获于核苷酸空口袋构象而阻断 GPCR 下游信号传导,从而抑制 Gαq 介导的钙释放、Gαs 介导的 cAMP 生成以及 GPCR 调控的癌细胞侵袭,在体外能有效克制多种临床多药耐药株,并通过激活 Caspase-3 和剪切 PARP 诱导肿瘤细胞凋亡 (apoptosis),还可抑制 Neu1-MMP-9-GPCR 信号平台的活化及下游 NF-κB 激活,可广泛用于肺癌、胰腺癌、乳腺癌、黑色素瘤、白血病等癌症信号通路及炎症相关研究。
产品编号: MS-N76552 CAS No.: 195450-11-4 分子式: C22H30N4Os 分子量: 398.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BIM-46174 是一种异源三聚体 G 蛋白复合物 (G protein) 抑制剂,通过将 Gα 蛋白捕获于核苷酸空口袋构象而阻断 GPCR 下游信号传导,从而抑制 Gαq 介导的钙释放、Gαs 介导的 cAMP 生成以及 GPCR 调控的癌细胞侵袭,在体外能有效克制多种临床多药耐药株,并通过激活 Caspase-3 和剪切 PARP 诱导肿瘤细胞凋亡 (apoptosis),还可抑制 Neu1-MMP-9-GPCR 信号平台的活化及下游 NF-κB 激活,可广泛用于肺癌、胰腺癌、乳腺癌、黑色素瘤、白血病等癌症信号通路及炎症相关研究。

生物实验数据

生物活性 BIM-46174 is an inhibitor of the heterotrimeric G protein complex (G protein) that blocks GPCR downstream signaling by trapping Gα proteins in a nucleotide-free pocket conformation, thereby inhibiting Gαq-mediated calcium release, Gαs-mediated cAMP production, and GPCR-regulated cancer cell invasion; it effectively counteracts multiple clinical multidrug-resistant strains in vitro and induces tumor cell apoptosis (apoptosis) through activation of Caspase-3 and cleavage of PARP, and it also inhibits activation of the Neu1-MMP-9-GPCR signaling platform and downstream NF-κB activation, making it broadly applicable to research on cancer signaling pathways and inflammation in lung cancer, pancreatic cancer, breast cancer, melanoma, leukemia, and other cancers.
IC50 & Target

NTR1

0.7 μM (IC50)

MMP-9

 

MMP-3

 

TLR7

7.94 μM (IC50)

TLR9

20 μM (IC50)

Wnt2

 

Caspase 3

 

体外研究
(In Vitro)

BIM-46174 (1-100 μM;1 h) 在人乳腺癌细胞 MCF-7 中作为异源三聚体 G 蛋白抑制剂,能显著且可逆地阻断霍乱毒素或血管活性肠肽介导的 cAMP 通路激活。
BIM-46174 (5-30 μM;1-24 h) 能选择性抑制黑色素瘤细胞 A2058 中内皮素-1 偶联的胞内钙释放,并显著逆转或消除由 Wnt-2/3a 或神经降压素诱导的结直肠癌细胞 HCT8/S11、肺癌细胞 LNM35 和结肠癌细胞 HT29 的侵袭活性 (IC50 = 0.7 μM)。
BIM-46174 (0.6-30 μM;72-96 h) 对广泛的人类癌细胞展现出强效的体外抗增殖活性,其 IC50 范围为 0.6-25 μM能有效克制多种临床多药耐药株,并通过激活 Caspase-3 和剪切 PARP 诱导肿瘤细胞凋亡。
BIM-46174 (10-200 μM;30 min-24 h) 在巨噬细胞 (RAW-blue/RAW264.7) 中,通过切断上游 G 蛋白信号显着阻断Imiquimod (MS-W79117) 或核酸诱导的 TLR7/9 活化及下游 MyD88 接头蛋白招募,进而抑制 NF-κB 的磷酸化激活及促炎细胞因子 (TNFα、MCP-1/CCL2) 的分泌释放。
BIM-46174 (10-30 μM;1-30 min) 在 3T3-hEGFR 细胞及人胰腺癌细胞 (PANC-1/MiaPaCa-2) 中,能通过阻断上游 G 蛋白有效抑制由表皮生长因子 (EGF) 刺激引起的受体后水平 Neu1 神经氨酸酶活化,从而直接阻断下游表皮生长因子受体 (EGFR) 的自身磷酸化激活。
BIM-46174 (100 μM;2 h) 在人胚肾细胞 HEK293 中,能对Carbachol (MS-U27390) 激活引发的 Gαq 蛋白依赖性第二信使 myo-inositol 1-phosphate (IP1) 的胞内积累表现出强烈的抑制活性。

Cell Proliferation Assay

Cell Line: A-427, PC3, HL60, CCRF-CEM, MIA PaCa-2, NCI-H69, U-87MG, A2058, HT29, and DU145 cells
Concentration: 0.6-25 μM
Incubation Time: 96 h
Result: Inhibited the in vitro proliferation of a large panel of human cancer cell lines, including various anticancer drug-resistant variants, with significantly lower resistance factors than reference drugs.

Apoptosis Analysis

Cell Line: HL60 and NCI-H69 cells
Concentration: 30 μM
Incubation Time: 72 h
Result: Resulted in a significant 5-fold increase in apoptosis and induced caspase-3 activation along with cleaved PARP appearance.

Cell Invasion Assay

Cell Line: HCT8/S11, LNM35, HT29, and MDCKts.src cells
Concentration: 5 μM
Incubation Time: 24h
Result: Abrogated or completely reversed the invasive potential induced by Wnt-2, Wnt-3a, neurotensin, or aluminium fluoride, but showed no effect on invasion induced by constitutively activated Gα12, Gα13, or Gβ1γ2 dimers.

Western Blot Analysis

Cell Line: RAW-blue and RAW264.7 macrophage cells
Concentration: 20 μM
Incubation Time: 30 min
Result: Inhibited imiquimod- and ODN-induced NF-κB pSer536 activation in the cytoplasmic cell lysates.

Western Blot Analysis

Cell Line: 3T3-hEGFR cells
Concentration: 20 μM
Incubation Time: 30 min
Result: Inhibited EGF-induced EGFR tyrosine kinase receptor phosphorylation in cell lysates.
体内研究
(In Vivo)

BIM-46174 (20 或 25 mg/kg;腹腔注射;25 mg/kg 每日2次,14天,或 20 mg/kg 每日2次,5天) 在人小细胞肺癌 NCI-H69 异种移植瘤模型中单药活性有限,但联合Cisplatin (MS-E94993) 或法尼基转移酶抑制剂治疗均能显著降低肿瘤生长速度,且毒性反应轻微。
BIM-46174 (25 mg/kg;腹腔注射;每日2次,8天) 在人非小细胞肺癌 LNM35 异种移植瘤模型中,联合Cisplatin (MS-E94993) (1 mg/kg,每日1次,连续5天) 能显著降低肿瘤生长速度,且表现出良好的耐受性和较低的全身毒性。
BIM-46174 (20 mg/kg;腹腔注射;每日2次,5天) 在人胰腺癌 MIA PaCa-2 异种移植瘤模型中,联合拓扑异构酶抑制剂 BN80927 (MS-E86086) 可显著延缓肿瘤生长速度,表现出协同抗肿瘤作用,并在整个过程中保持良好的安全性。
BIM-46174 (2 mg/kg/h;持续静脉输注;6 天) 在大鼠持续输注毒性评估模型中,被确认为引发显著体重减轻前的最高可耐受剂量,且未观察到关键生化指标的明显异常。

Animal Model: SCLC NCI-H69 tumor xenograft model (Female athymic NCr-nu/nu mice, 4-6 weeks)
Dosage: 20 or 25 mg/kg
Administration: Intraperitoneal injection (i.p.); 25 mg/kg twice daily for 14 days, or 20 mg/kg twice daily for 5 days
Result: Showed that administered alone at 25 mg/kg or 20 mg/kg resulted in minimal tumor growth inhibition.
Demonstrated that combined treatment with Cisplatin (MS-E94993) (1.5 mg/kg for 5 consecutive days) induced a drastic and significant reduction of the tumor growth rate.
Revealed that combination therapy with the farnesyltransferase inhibitor produced significant antitumor activity.
Observed a limited and acceptable body weight loss across all combination treatment groups, indicating minimal systemic toxicity.
Animal Model: NSCLC LNM35 tumor xenograft model (Female athymic NCr-nu/nu mice, 4-6 weeks)
Dosage: 25 mg/kg
Administration: Intraperitoneal injection (i.p.); twice daily for 8 days
Result: Demonstrated that combined treatment with Cisplatin (MS-E94993) (1 mg/kg for 5 consecutive days) achieved a drastic and statistically significant reduction in the tumor growth rate compared to the vehicle or single-agent groups.
Associated with minimal toxicity, presenting only a limited and acceptable body weight loss in the treated animals.
Animal Model: Pancreatic cancer MIA PaCa-2 tumor xenograft model (Female athymic NCr-nu/nu mice, 4-6 weeks)
Dosage: 20 mg/kg
Administration: Intraperitoneal injection (i.p.); twice daily for 5 days
Result: Revealed that combination therapy with the topoisomerase inhibitor (MS-E86086) (2 mg/kg twice daily for a 14-day cycle) induced a profound and highly significant delay in the pancreatic tumor growth rate.
Maintained a safe safety profile with minimal toxicity and limited body weight loss observed throughout the regimen.
Animal Model: Continuous infusion toxicity evaluation in rats
Dosage: 2 mg/kg/h
Administration: Continuous intravenous infusion for 6 days
Result: Established this regimen as the highest tolerable dose before triggering significant body weight loss after 6 days of continuous delivery.
Showed no significant pathopharmacological changes in key biochemical blood markers, including urea, creatinine, glycemia, γ-glutamyl transpeptidase, aspartate aminotransferase, and alanine aminotransferase, indicating no significant liver or kidney dysfunction.

化学信息

分子量 398.56
分子式 C22H30N4Os
CAS No. 195450-11-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础